Lupin has received USFDA approval to market a generic version of Topiramate extended-release capsules for the treatment of seizures in patients aged 6 and older.
New Delhi, Jul 12 (PTI) Drug firm Lupin on Friday said it has received approval from the US health regulator to market a generic medication to treat seizures.
The company has received approval from the US Food and Drug Administration (USFDA) to market Topiramate extended-release capsules in the US, the drug firm said in a statement.
The product is a generic equivalent of Supernus Pharmaceuticals, Inc.'s Trokendi XR extended-release capsules, it added.
Topiramate extended-release capsules are indicated for the treatment of seizures in patients six years of age and older.
As per IQVIA MAT, Topiramate extended-release capsules had an estimated annual sale of USD 253 million in the US.
Shares of Lupin ended 1.04 per cent lower at Rs 1,798 apiece on the BSE.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback